Back To: Home : Featured Technology : Gene and Cell Therapies

CLICK HERE FOR WHAT'S NEW IN:
 

Tekmira sees promise in TKM-HTG
May 2015
SHARING OPTIONS:

VANCOUVER, British Columbia—The Keystone Symposia Conference: Liver Metabolism and Nonalchoholic Fatty Liver Diseases in March saw Tekmira Pharmaceuticals Corp. share new preclinical data on TKM-HTG, its RNAi therapeutic candidate for the treatment of hypertriglyceridemia. The most important finding resulting from the preclinical studies, as seen in a mouse model fed a high-fat containing diet, is the super-additive effects on plasma triglycerides that result from silencing the apolipoprotein C3 (apoC3) and angiopoietin-like protein 3 (ANGPTL3) genes expressed in the liver. In the human apoC3-Tg mouse model, silencing the apoC3 gene resulted in rapid, potent and sustained plasma triglyceride lowering, and the gene silencing and triglyceride-lowering effects from a single administration lasted for more than two weeks. Encouraging cholesterol profile changes and significant glucose-lowering effects were also seen.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.